Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amarin Corporation Plc (AMRN)
NASDAQ:AMRN
Holding AMRN?
Track your performance easily
AMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.57 - $1.37
Previous Close$0.6
Volume88.76K
Average Volume (3M)1.29M
Market Cap
$242.56M
Enterprise Value-$65.87M
Total Cash (Recent Filing)$320.70M
Total Debt (Recent Filing)$8.74M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 06, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding411,171,121
10 Day Avg. Volume638,101
30 Day Avg. Volume1,289,319
Standard Deviation0.24
R-Squared0.18
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)0.93
Price to Cash Flow (P/CF)-22.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit-0.40
Enterprise Value/Ebitda1.25
Forecast
1Y Price Target
$1.00Price Target Upside69.49% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Amarin News
PremiumPress Releases
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
PremiumCompany Announcements
Amarin Announces New CEO Aaron Berg and Incentive PlanBulls Say, Bears Say
Bulls Say
Financial StabilityAmarin ended the second quarter with $307 million in cash and investments, ensuring strong support for continued operations.
Operational EfficiencyAmarin’s tighter operational expense management has resulted in significant savings, achieving approximately $50 million in annualized savings, surpassing their initial goal.
Revenue PerformanceTotal revenue of $67.5 million came in significantly above consensus estimates, driven by the recognition of a $15 million milestone payment.
Bears Say
CompetitionUS Vascepa continues to face rising generic competition and pricing pressure, which could intensify due to challenges in retaining some exclusive accounts.
Market AccessA large US national pharmacy benefit manager informed Amarin that it will no longer cover Vascepa as the exclusive icosapent ethyl product for its commercial national formularies, affecting a significant portion of the US Vascepa business.
RevenueTotal product revenue for 2Q24 was $47.5mn, down -27% y/y from 2Q23.
---
Ownership Overview
19.76% Insiders
0.53% Mutual Funds
15.17% Other Institutional Investors
64.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMRN FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was $0.57 and its highest was $1.37 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Currently, no data Available
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Jul 31, 2024. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.042 by $0.042.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Undervalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -$0.06.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 411,171,100 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of $0 in its last earnings report, beating expectations of -$0.042. Following the earnings report the stock price went down -12.821%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Among the largest hedge funds holding Amarin Corporation Plc’s share is SCP Investment, LP. It holds Amarin Corporation Plc’s shares valued at 2M.
---
Amarin Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.00 (69.49% Upside)
$1.00 (69.49% Upside)
Blogger Sentiment
Bullish
AMRN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $102.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.53%
12-Months-Change
Fundamentals
Return on Equity
-5.97%
Trailing 12-Months
Asset Growth
-7.00%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
---
AMRN Company Deck
---
AMRN Earnings Call
Q2 2024
0:00 / 0:00
---
AMRN Stock 12 Month Forecast
Average Price Target
$1.00
▲(69.49% Upside)
Technical Analysis
Amneal Pharmaceuticals
―
Corcept Therapeutics
―
Bausch Health Companies
―
Corbus Pharmaceuticals
―
Best Analysts Covering AMRN
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+28.29%
reiterated a sell rating 2 months ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +28.29% per trade.
---